ABSI
AbsciDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
A successful licensing deal or a positive platform-driven discovery outcome re-rates Absci toward a mid-single-digit multiple as revenue visibility improves and dilution is minimized.
Posture
Defensive
Lead driver
Momentum
What changed
1 setup hits (3d) with net bullish as of 2026-06-02.
What can break
Failure to secure partners or the need for dilutive financing amid continued R&D expenses drives the share down materially; limited near-term revenue keeps downside elevated.
Momentum
97
Value
41
Sentiment
0
Setup hits (3d)
1 · Net Bullish
AI TargetsBase $2.34 · Bull $4.21 · Bear $1.17
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-17 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Bullish
Target $8.05
Why
Momentum97 · Δ7d -0.1
Value41 · Δ7d +0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
97
34% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.9
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
0
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade D. Momentum 97.0 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$1.02B
Beta
2.13
Shares Out
150.37M
P/E (TTM) · Derived
-7.2
P/S (TTM)
199.78
P/FCF (TTM) · Derived
-10.53
Rev YoY
-77.8%
EPS YoY
+17.2%
Gross Margin
-
Op Margin
-4261.1%
Net Debt
-$108.36M
Current Ratio
5.89
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology